Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day.
When administered on a chronic high-dosage regimen, enteric-coated aspirin granules produced significantly less gastric damage than plain aspirin or aspirin-antacid combinations. Clinically meaningful damage occurred in all subjects receiving plain aspirin, 93% of those receiving aspirin-antacid combination and only 27% and 20% of those receiving enteric-coated aspirin granules qid and bid, respectively. All three aspirin formulations were taken as 1 g qid (4 g/day) and an additional group received enteric granules administered as 2 g bid (4 g/day). Gastric damage was assessed by means of endoscopy carried out after seven days of treatment. Enteric granules are equally safe when administered on a bid or qid regimen (at same total daily dosage) and, in a bid regimen, should provide a compliance advantage for patients on high-dose therapy for diseases such as rheumatoid arthritis.
D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004386:Duodenum / Q000473:pathology; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013270:Stomach / Q000473:pathology; D013276:Stomach Ulcer / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D013608:Tablets, Enteric-Coated
D013608:Tablets, Enteric-Coated; D001241:Aspirin